Lorenza Marotti

Dr. Lorenza Marotti


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MSMargherita Serra
Margherita Serra
ALA. Quattrini Li
A. Quattrini Li
LCL. Cataliotti
L. Cataliotti
ECE. Cianchetti
E. Cianchetti
FCFabio Corsi
Fabio Corsi
VTV.L. Troilo
V.L. Troilo

23 April 2018 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
GSGabriele Schnapper
Gabriele Schnapper
LMLorenza Marotti
Lorenza Marotti
DCDenise Casella
Denise Casella
MMMaria P. Mano
Maria P. Mano
RMRobert E. Mansel
Robert E. Mansel
AVA. Valnegri
A. Valnegri


2 August 2022
Verified
Book Chapter
Closed access
PDF file
LMLorenza Marotti
Lorenza Marotti
IRIsabel Teresa Rubio
Isabel Teresa Rubio
LCLuigi Cataliotti
Luigi Cataliotti

3 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FMFederica Martorana
Federica Martorana
Damiano GentileDamiano Gentile
Damiano Gentile
MTMariano Tomatis
Mariano Tomatis
APAntonio Ponti
Antonio Ponti
LMLorenza Marotti
Lorenza Marotti
OGon behalf of the EUSOMA Working Group
on behalf of the EUSOMA Working Group
Background: Optimal management of breast cancer (BC) patients with pathological complete response (pCR) after neoadjuvant therapy (NAT) remains debated. We performed a retrospective analysis to evaluate whether the extent of surgery influences survival outcomes in this patient population. Methods: Using the EUSOMA database, we retrospectively collected data of women with pCR after NAT, excluding those with BRCA1/2 mutations. The cohort was stratified by surgery type, i.e., breast-conserving surgery (BCS) or mastectomy. Relapse-free survival (RFS) and overall survival (OS) were compared using Cox regression. Results: Of 467 patients, 327 (70.0%) underwent BCS and 140 (30.0%) underwent mastectomy. Women treated with mastectomy were more likely to have multifocal tumors and advanced disease. After a median follow-up of 5.6 years, 7.3% of patients experienced BC recurrence. Axillary nodal involvement (cN+) and mastectomy were independently associated with recurrence, occurring in 11.4% of cN+ compared to 3.7% of cN0 patients (HR 3.02; 95% CI: 1.40–6.51; p = 0.005) and in 12.5% of mastectomy vs. 5.2% of BCS patients (HR 2.08; 95% CI: 1.05–4.11; p 0.035). cN+ patients also showed significantly higher mortality rates (9.4% vs. 1.6% of cN0; HR 6.16; 95%CI: 2.09–18.17; p = 0.001). However, surgery type did not impact OS. Conclusions: In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy. Baseline nodal involvement independently predicted recurrence and mortality; however, the type of surgery did not impact OS. These findings support BCS as a safe treatment option for this patient population.